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Aim: To investigate the effectiveness of IgM-enriched immunoglobulins (IgM-eIVIG) in reducing short-term mortality
of neonates with proven late-onset sepsis.
Methods: All VLBW infants from January 2008 to December 2012 with positive blood culture beyond 72 hours of
life were enrolled in a retrospective cohort study. Newborns born after June 2010 were treated with IgM-eIVIG,
250 mg/kg/day iv for three days in addition to standard antibiotic regimen and compared to an historical cohort
born before June 2010, receiving antimicrobial regimen alone. Short-term mortality (i.e. death within 7 and 21 days
from treatment) was the primary outcome. Secondary outcomes were: total mortality, intraventricular hemorrhage,
necrotizing enterocolitis, periventricular leukomalacia, bronchopulmonary dysplasia at discharge.
Results: 79 neonates (40 cases) were enrolled. No difference in birth weight, gestational age or SNAP II score
(disease severity score) were found. Significantly reduced short-term mortality was found in treated infants
(22% vs 46%; p = 0.005) considering all microbial aetiologies and the subgroup affected by Candida spp. Secondary
outcomes were not different between groups.
Conclusion: This hypothesis-generator study shows that IgM-eIVIG is an effective adjuvant therapy in VLBW infants
with proven sepsis. Randomized controlled trials are warranted to confirm this pilot observation.
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An immature innate immune response is a major factor in
the high rate of systemic infections among very low birth
weight newborns. Preterm babies have less endogenous
immunoglobulins whose transplacental transfer mainly
occurs after 32 weeks of gestation [1-4]. Intravenous im-
munoglobulins supplementation is therefore an appealing
strategy to fight neonatal sepsis.
A recent international, randomised trial, INIS study, on
standard immunoglobulins (S-IVIG) added to antibiotic
therapy in neonates with suspected infection concluded that
S-IVIG had no effect on death or major disability at the age
of 2 years [5]. The results of INIS study also constitute the
database of a recent Cochrane review on the use of Ig for
sepsis in neonate [6]. Yet, the outcome of neonatal sepsis* Correspondence: letizia.capasso@gmail.com
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reproduction in any medium, provided the ormight benefit from different IVIG preparations. Natural
IgM antibodies play an important role in clearing pathogens,
enhancing immune responses, and preventing autoimmun-
ity, thus Ig-M enriched immunoglobulins (IgM-eIVIG) may
have a strong therapeutic potential. In adult septic patients,
the use of IgM-eIVIG as an adjuvant to antibiotic therapy
has led to a significant reduction in disease severity or mor-
tality rate in the Intensive Care Units [7,8]. There are limited
data on passive immunotherapy with IgM-eIVIG in septic
neonates and no specific report is focused on VLBW babies
though they have the highest risk of invasive infection. We
have then conducted a retrospective, cohort study on the
use of IgM-eIVIG in addition to antibiotic therapy in VLBW
neonates with late onset sepsis as an hypothesis generator
for future prospective clinical trials.Methods
The charts of consecutive VLBW infants included in the
local section of the Vermont Oxford Network (VON)l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Main characteristics of the whole study population
IgM-eIVIG Treated Untreated
n = 40 n = 39 p
Gestational age (weeks) 27 ± 2,6 27,6 ± 3,9 NS
Birth weight (grams) 924 ± 277 951 ± 362 NS
Snap II score 15 ± 13 12 ± 9 NS
Cesarean section 39 (59%) 38 (58%) NS
Prenatal steroids 32 (48%) 39 (60%) NS
CRP positive 51 (77%) 49 (75%) NS
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of 491 neonates were reviewed . Neonates were born at the
Università “Federico II” di Napoli, the largest delivery place
in the Naples regional area assisted by a level III NICU. In-
clusion criterium was the diagnosis of blood culture-proven
late onset sepsis (i.e. sepsis occurring after 72 hours of life)
in VLBW infants.
For defining blood culture as positive, we adopted the
Vermont Oxford Network criteria, i.e.:
– sepsis by coagulase negative staphylococcus:
pathogen recovered from either a central line, or
peripheral blood sample in association to one or
more signs of generalized infection and treatment
with 5 or more days of intravenous antibiotics after
the above cultures were obtained;
– sepsis by other bacteria: bacterial pathogen
recovered from blood culture;
– sepsis by fungi: fungus recovered from a blood
culture obtained from either a central line or
peripheral blood sample [9].
Clinical signs for the diagnosis of generalized infection
were: apnoea, mottled skin, temperature instability, feeding
intolerance, significant abdominal distension, respiratory
distress or hemodynamic instability. Laboratory criteria used
were elevated CRP (cut off =1 mg/dL), abnormal leukocyte
count (cut off less than 5.000/μl or more than 20.000/μl)
and I/T ratio (cut off >0.2). To assess the clinical severity
of cases and controls at enrollment, we used the SNAP
II score, a composite index of six physical parameters
(hypotension, hypothermia, acidosis, PO2/FiO2 ratio,
multiple seizures, urinary output) initially designed for
NICU admission [10]. A recent study validated the SNAP
II score as a accurate mortality predictor at the onset of
severe neonatal sepsis [11]. For this study, SNAP II score
was calculated for each patients using parameters reported
in the charts in the first 24 hours sepsis was suspected
(i.e. when clinical deterioration was reported, blood work
was done and antibiotics were started).
Exclusion criteria were: congenital anomalies, TORCH
group infections, primary immunodeficit.
Intravenous antibacterial therapy used throughout the
study was teicoplanin (loading dose 16 mg/Kg followed
by 8 mg/Kg q 24 hours) and meropenem (20 mg/Kg q
8 hours).
In the event of a positive blood culture for Candida spp.,
antibiotic therapy was withdrawn and a standard antifungal
regimen (liposomal amphotericin B: 5 mg/kg/die) was used
for 3 weeks.
Starting from June 1st 2010, IgM-eIVIG (Pentaglobin®
Biotest Germany) 250 mg/kg/day i.v. for three days was
added to the NICU protocol for sepsis treatment in the first
24 hours sepsis was suspected when antibiotic therapy wasstarted. In order to compare neonates before and after the
introduction of IgM-eIVIG in our clinical practice, meticu-
lous care was exerted to ascertain that no other major
change had been made that could have been relevant
to the study outcome (i.e. central lines managing and
duration; fluconazole prophylaxis against invasive fungal
infections; handwashing and other general prophylactic
measures; management of enteral nutrition).
VLBW preterms with late onset sepsis may have a
prolonged hospital stay after a septic episode and their
demise might be related to many factors other than infec-
tion; therefore, short-term mortality (i.e. death within 7 and
21 days from treatment) was an appropriate primary
outcome for this study. Secondary outcome measures
were: in-hospital total mortality, rates of intraventricular
hemorrhage, periventricular leukomalacia, necrotizing
enterocolitis, bronchopulmonary dysplasia at discharge.
Statistical analysis
ANOVA was used to compare the main characteristics of
study population between treated and untreated neonates
with IgM-eIVIG; to evaluate the strength of association
or non –indipendence between two binary data values,
odds ratios with confidence interval were calculated with
SPSS 19.0 software (IBM Corporation, NY); p ≤ 0.05 was
considered statistically significant.
Results
Of the 82 VLBW infants enrolled, 2 neonates were ex-
cluded for congenital anomalies and one for TORCH
infection; of the remaining 79 (see demographics in Table 1),
40 patients received antibiotics in association to IgM-eIVIG
and 39 received antibiotic treatment alone. No difference in
birth weight, gestational age or SNAP II score was found.
All enrolled infants had a positive blood culture and their
microbiology is given in Figure 1.
Mortality at 7 and 21 days coincided. IgM-eIVIG treated
infants had a significantly lower short term mortality than
untreated (OR 0.16; 95% CI: 0.3-0.7<, p = 0,005). Secondary
outcomes were not significantly different between cases
and controls (Table 2).
In a subgroup analysis of neonates with Candida spp.

































Figure 1 Main pathogens isolated from blood cultures.
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treated group versus 8/15 (53%) deaths in untreated
group (OR 0.1; 95% CI: 0.01-0.97, p = 0.047).
An accurate review of patients’ charts did not show acute
reactions compatible with IgM-eIVIG infusion.
Discussion
This pilot retrospective study shows that IgM-eIVIG are
effective in reducing short-term mortality in VLBW in-
fants with proven sepsis. When compared with S-IVIG,
IgM-eIVIG show more efficient complement activation,
better opsonisation, greater neutralization of the strepto-
coccal superantigen SpeA and better binding both to
bacterial antigens and toxins all possibly due to their
pentameric structure [12]. This biological background
together with our retrospective observation may increaseTable 2 Primary and secondary outcomes of the whole
study population
IgM-eIVIG Treated Untreated
n = 40 n = 39 OR (95%CI) p
Short term mortality 9 (22%) 18 (46%) 0.16 (0.3-0.7) 0,005*
Total mortality 17 (44%) 18 (46%) 0.46 (0.9-1.8) NS
IVH 9 (22%) 8 (20%) 1.17 (0.5-2.7) NS
PVL 3 (7,5%) 2 (3%) 2.6 (0.5-14) NS
NEC 2 (6%) 1 (3%) 2 (0.4-11) NS
BDP 4(10%) 4 (10%) 0.97(0.2-4.2) NS
*p < 0.05 (IVH: intraventricular hemorrhage, PVL: periventricular leukomalacia,
NEC: necrotizing enterocolitis, BPD: bronchopulmonary dysplasia).the interest towards this strategy for IgM-eIVIG in VLBW
infants with sepsis despite the paucity and somewhat
conflicting specific clinical evidence in the literature.
In a randomized trial of 60 Saudi septic neonates of
various gestational ages, Haque showed that IgM-eIVIG
significantly decreased total mortality [13]. In a separate
paper, the same author showed on a cohort of 195 neonates
that IgM-eIVIG but not S-IVIG were effective in decreasing
mortality [14]. These reports do not clearly indicate their
general sepsis rate prevalence, making their results hard to
compare. A negative conclusion was drawn in the study by
Erdem et al. working, though, with a likely underpowered
sample cohort [15].
With a larger population we detect a clinically relevant
difference focusing only on the most susceptible babies.
Under the standard conditions of VON, we show an effect
of IgM-eIVIG on short term mortality on those babies
who had culture proven sepsis.
Unlike the Haque series, our most prevalent pathogens
were fungi against which IgM-eIVIG proved to be very
effective. Over the study period, our incidence of Candida
spp. positive blood cultures was above the Italian average
but mostly below the third quartile when compared to the
local section of the VON database. We later found out that
the IgM-eIVIG used had an average anti C. albicans specific
titer of 1.618 U/ml of IgG, 171 U/ml of IgA, 194 U/ml of
IgM (courtesy of the manifacturer). The explanation for
this novel observation may be related to the dominant
protective role of antibodies against disseminated can-
didiasis. In fact, antibody opsonization is crucial to op-
timal Candida phagocyting and killing by neutrophils
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mannan antigens activate complement [16].
Our retrospective study was focused strictly on short-
term mortality on the assumption that a therapeutic advan-
tage of immunotherapy would be easier to demonstrate.
Total mortality is influenced by many variables other than
sepsis acting long after the resolution of an infection in
a ELBW or VLBW infant. It is not surprising, therefore,
that short term and total mortality may differ and that
secondary outcomes were not significantly different
between cases and controls.
Despite the encouraging results, our study finds the
main limitation in its observational nature; however,
searching for confounders, we were not able to detect
significant change of NICU practices or outcome variations
in the study period. Also, mortality is an immediate
clear-cut endpoint.
Conclusion
This hypothesis-generator study shows that IgM-eIVIG is
an effective adjuvant therapy in VLBW infants with proven
sepsis reducing short term mortality.
We believe that this analysis fulfilled its original purpose
to set the ground for larger, randomized prospective trials.
Given the considerable burden of morbidity and mortality
imposed by neonatal sepsis, new research should urgently
be addressed not only to validate our results but also to
tailor the optimal scheme of treatment.
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